Tenofovir disoproxil fumarate

The main ingredient of this product is tenofovir disoproxil fumarate, and its chemical name is: 9-((R)-2-((bis(((isopropoxycarbonyl)oxy(methoxy)phosphinyl)-propyl)adenine fumarate (1:1). Chemical structure: Molecular formula: C19H30N5O10.C4H4O4 Molecular weight: 635.52

Didanosine: Caution should be exercised when co-administering tenofovir disoproxil fumarate and didanosine, and patients receiving the co-administration should be closely monitored for didanosine-related adverse events. Didanosine should be discontinued in patients who experience adverse reactions related to didanosine. The maximum serum concentration (Cmax) and area under the plasma concentration-time curve (AUC) of didanosine were significantly increased when co-administered with tenofovir disoproxil fumarate (see [Pharmacokinetics]). The mechanism of this interaction is not clear. Higher didanosine concentrations may lead to didanosine-related adverse reactions, including pancreatitis and neuropathy. Decreased CD4 cell counts were observed in patients receiving tenofovir disoproxil fumarate and didanosine 400 mg per day. In patients weighing 60 kg, the dose of didanosine enteric-coated should be reduced to 250 mg per day when co-administered with tenofovir disoproxil fumarate. In patients weighing 60 kg, the dose of didanosine enteric-coated should be reduced to 250 mg per day when co-administered with tenofovir disoproxil fumarate.

This product is a compound preparation, each tablet contains 300 mg of lamivudine and 300 mg of tenofovir disoproxil fumarate

1. Drugs that affect renal function Because tenofovir is mainly cleared through the kidneys, the co-administration of lamivudine-tenofovir tablets with drugs that can cause reduced renal function or compete with active tubular clearance can increase the serum concentration of tenofovir and/or increase the concentration of other drugs cleared through the kidneys. Such drugs include but are not limited to cidofovir, acyclovir, valacyclovir, gamclovir, ganciclovir, aminoglycosides (such as gentamicin) and large or multiple doses of NSAIDs (see [Precautions]). 2. HIV-1 protease inhibitor tenofovir disoproxil fumarate can reduce the AUC and Cain of atazanavir (see (pharmacokinetics)). When used in combination with lamivudine and tenofovir disoproxil tablets, it is recommended to administer atazanavir 300 mg and ritonavir 100 mg simultaneously. Tenofovir disoproxil fumarate should not be used in combination with atazanavir alone (without ritonavir). Studies have shown that lopinavir/ritonavir, atazanavir combined with ritonavir, and darunavir combined with ritonavir will increase the concentration of tenofovir (see (pharmacokinetics)). Patients receiving lamivudine and tenofovir tablets should not be used in combination with lopinavir/ritonavir or darunavir combined with ritonavir. Ritonavir-boosted darunavir should monitor for adverse events related to tenofovir disoproxil fumarate. If patients experience adverse events related to tenofovir disoproxil fumarate or ritonavir-boosted darunavir, this product should be discontinued. 3. When the hepatitis C antiviral drugs tenofovir disoproxil fumarate (one of the components of this product) are co-administered with sofosbuvir/velpatasvir or ledipasvir/ziruofosbuvir, the exposure to tenofovir will be increased (see (Pharmacokinetics)). If patients use this product and sofosbuvir/velpatasvir in combination, they should monitor for adverse events related to tenofovir disoproxil fumarate. If patients use this product in combination with lediyuanvir/fosbuvir and do not use the combination of HIV-1 protease inhibitors/ritonavir or HIV-1 protease inhibitors/cobicistat, they should monitor for adverse reactions related to tenofovir disoproxil fumarate. If patients use the combination of HIV-1 protease inhibitors/ritonavir or HIV-4-1 protease inhibitors/cobicistat when using this product in combination with lediyuanvir/fosbuvir, the safety of increased tenofovir concentrations in this regimen has not been confirmed, and patients should consider using this regimen as an alternative to HCV antiretroviral therapy. If combination therapy is required, adverse reactions related to tenofovir disoproxil fumarate should be monitored. Should. 4. Lamivudine (one of the components of this product), an organic cation transporter inhibitor, is mainly eliminated in the urine via active organic cations. The possibility of interactions between lamivudine and other concomitantly used drugs should be considered, especially for drugs whose main clearance pathway is through active secretion in the kidneys via organic cation transport systems (such as trimethoprim) (see [Pharmacokinetics]). There are currently no relevant research data. 5. Sorbitol Co-administration of a single dose of lamivudine and sorbitol will result in a dose-dependent decrease in lamivudine exposure. If possible, avoid the combined use of drugs containing sorbitol and lamivudine (see (Pharmacokinetics 1)).